ASP Isotopes Inc. Announces Pricing of Public Offering of Common Stock
ASP Isotopes (NASDAQ: ASPI) priced an underwritten public offering of 17,167,380 shares of common stock for gross proceeds of approximately $210.3 million, before underwriting discounts, commissions and offering expenses.
The offering is expected to close on October 16, 2025, subject to customary closing conditions. The company granted the underwriters a 30‑day option to purchase additional shares for approximately $31.5 million at the offering price. Cantor and Lucid Capital Markets are joint book‑running managers. The company intends to use net proceeds for general corporate purposes including working capital, operating expenses and capital expenditures.
ASP Isotopes (NASDAQ: ASPI) ha annunciato una offerta pubblica sottoscritta di 17,167,380 azioni ordinarie per proventi lordi di circa 210,3 milioni di dollari, prima di sconti, commissioni e spese di offerta.
L'offerta dovrebbe chiudersi il 16 ottobre 2025, soggetta alle condizioni di chiusura usuali. L'azienda ha concesso agli underwriter una opzione di 30 giorni per acquistare azioni aggiuntive per circa 31,5 milioni di dollari al prezzo di offerta. Cantor e Lucid Capital Markets sono co-responsabili della gestione della collocazione. L'azienda intende utilizzare i proventi netti per scopi aziendali generali tra cui capitale circolante, costi operativi e spese in conto capitale.
ASP Isotopes (NASDAQ: ASPI) fijó una oferta pública suscrita de 17,167,380 acciones comunes por un ingreso bruto de aproximadamente 210,3 millones de dólares, antes de descuentos de suscripción, comisiones y gastos de oferta.
Se espera que la oferta cierre el 16 de octubre de 2025, sujeto a condiciones de cierre habituales. La empresa concedió a los suscriptores una opción de 30 días para comprar acciones adicionales por aproximadamente 31,5 millones de dólares al precio de la oferta. Cantor y Lucid Capital Markets son los coordinadores de libro conjuntos. La empresa tiene la intención de utilizar los ingresos netos para usos corporativos generales, incluyendo capital de trabajo, gastos operativos y gastos de capital.
ASP Isotopes (NASDAQ: ASPI)가 17,167,380주의 보통주를 대상로 하는 인수주관 공개발행을 통해 총 2억 1,030만 달러의 매출을 기대합니다(발행비용, 인수수수료 및 배정비용 차감 전).
발행은 일반적으로 필요한 종결조건에 따라 2025년 10월 16일에 마감될 예정입니다. 회사는 인수주관사에게 발행가로 추가 주식을 30일간 매입할 수 있는 옵션을 약 3,150만 달러 규모로 부여했습니다. Cantor와 Lucid Capital Markets는 공동 북런너로서 운영합니다. 회사는 순매출금을 운전자본, 영업비 및 자본지출을 포함한 일반 기업용 목적에 사용할 예정입니다.
ASP Isotopes (NASDAQ: ASPI) a procédé à une offre publique souscrite de 17 167 380 actions ordinaires pour un produit brut d'environ 210,3 millions de dollars, avant rabais de souscription, commissions et frais d'offre.
L'offre devrait être clôturée le 16 octobre 2025, sous réserve des conditions de clôture habituelles. La société a accordé aux souscripteurs une option de 30 jours pour acheter des actions supplémentaires pour environ 31,5 millions de dollars au prix de l'offre. Cantor et Lucid Capital Markets sont des coordinateurs de livres conjoints. La société a l'intention d'utiliser le produit net pour des besoins généraux de l'entreprise, y compris le fonds de roulement, les dépenses d'exploitation et les dépenses d'investissement.
ASP Isotopes (NASDAQ: ASPI) hat eine unterzeichnete öffentliche Platzierung von 17.167.380 Stammaktien zu Bruttoerlösen von ca. 210,3 Mio. USD vor Underwritingrabatten, Provisionen und Emissionskosten angekündigt.
Die Platzierung wird voraussichtlich am 16. Oktober 2025 abgeschlossen, vorbehaltlich üblicher Abschlussbedingungen. Das Unternehmen hat den Underwritern eine 30-tägige Option eingeräumt, zusätzliche Aktien zum Angebotspreis für ca. 31,5 Mio. USD zu erwerben. Cantor und Lucid Capital Markets sind gemeinsame Book-Running-Manager. Das Unternehmen beabsichtigt, die Nettomittel für allgemeine Unternehmenszwecke einschließlich Working Capital, Betriebskosten und Kapitalausgaben zu verwenden.
ASP Isotopes (NASDAQ: ASPI) طرحت اكتتاباً عاماً مدروساً لــ 17,167,380 سهماً من الأسهم العادية مقابل عائد إجمالي يقارب 210.3 مليون دولار قبل خصومات الاكتتاب والعمولات وتكاليف العرض.
من المتوقع أن يغلق الاكتتاب في 16 أكتوبر 2025، رهناً بالشروط الاعتيادية للإغلاق. منحت الشركة للمكتتبين خياراً لمدة 30 يوماً لشراء أسهم إضافية بمبلغ يقارب 31.5 مليون دولار بالسعر المعروض. كانتر ولو سيد كابيتال ماركتس هما المدرجان المشتركان للكتاب. تنوي الشركة استخدام العائد الصافي للأغراض العامة للشركة بما في ذلك رأس المال العامل، ونفقات التشغيل، ونفقات رأس المال.
ASP Isotopes (NASDAQ: ASPI) 通过承销的公开发行定价,发行普通股共 17,167,380 股,总毛收益约为 2.103亿美元,在承销折扣、佣金和发行费用之前。
该发行预计将在 2025年10月16日 结束,前提是符合惯常的交割条件。公司授予承销商一个在发行价基础上以约 3150万美元 的金额购买额外股票的 30 天期权。Cantor 与 Lucid Capital Markets 为联合主承销商。公司拟将净募集资金用于一般企业用途,包括营运资金、经营支出和资本性支出。
- Gross proceeds of $210.3 million expected
- Underwriters granted a 30‑day option for an additional $31.5 million
- All offered shares sold by the company, providing direct corporate capital
- Issuance of 17,167,380 new shares may dilute existing shareholders
- Offering price reference: last sale price $14.05 on October 14, 2025, exposing timing risk
Insights
ASP priced a ~17.17M share offering to raise about
This raises cash directly for the company by selling 17,167,380 new shares, with a 30‑day underwriter option for roughly
Key dependencies and risks include issuance dilution to existing holders and final net proceeds reduced by fees and expenses. The filing notes the offering closes subject to customary conditions and follows a shelf registration effective
WASHINGTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the pricing of an underwritten public offering of 17,167,380 shares of its common stock for total gross proceeds of approximately
In addition, the Company has granted the underwriters a 30-day option to purchase approximately
Cantor and Lucid Capital Markets acted as joint book-running managers for the offering.
The underwriters may offer the shares from time to time for sale in one or more transactions on the Nasdaq Capital Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. On October 14, 2025, the last sale price of the shares as reported on the Nasdaq Capital Market was
The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses, and capital expenditures.
The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (“SEC”) on October 14, 2025, which was automatically effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor New York, New York 10022; Email: prospectus@cantor.com or Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements include, but are not limited to, statements regarding the Company’s anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and other statements that are not historical facts. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including: our ability to satisfy the closing conditions of the offering, the failure to obtain necessary regulatory and shareholder approvals for the proposed acquisition of Renergen; disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; significant transaction costs and unknown liabilities related to the proposed acquisition of Renergen; litigation or regulatory actions related to the proposed acquisition of Renergen; the outcomes of various strategies and projects undertaken by the Company; the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties; our ability to complete the proposed the construction and commissioning of our enrichment plant(s) or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. “Risk Factors” of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company’s subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
